$5.33
1.11%
Nasdaq, Apr 25, 10:02 pm CET
ISIN
US00289Y1073
Symbol
ABEO
Sector
Industry

Abeona Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
about 14 hours ago
The 'Undercovered' Dozen highlights 12 lesser-covered stocks, offering investment opportunities and fostering community discussion on their potential. Abeona Therapeutics is seen as a Buy due to promising FDA approvals for pz-cel and UX111, potentially transforming the company with its first commercial products by 2025. Plains GP Holdings offers stable cash flows and high dividends in the volat...
Positive
Seeking Alpha
7 days ago
Abeona's pz-cel gene therapy shows the most durable wound healing in RDEB patients with no treatment related severe adverse events. There have been no instances of Squamous Cell Carcinoma. The FDA's previous Complete Response Letter focused on manufacturing and control issues. Since those questions have been answered thoroughly, an approval is likely by April 29th. Pz-cel offers a durable, one-...
Positive
Seeking Alpha
15 days ago
Abeona Therapeutics is poised for significant growth in 2025, with potential FDA approvals for Pz-cel and UX111, driving our Buy rating. Pz-cel, targeting RDEB, shows promising clinical data and commercial prospects, with an expected FDA decision by April 29, 2025. UX111, aimed at MPS IIIA, also holds strong potential, with an FDA decision anticipated by August 18, 2025, and substantial market ...
Neutral
GlobeNewsWire
27 days ago
CLEVELAND, April 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
Seeking Alpha
about one month ago
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Greg Gin – Vice President-Investor Relations and Communications Vish Seshadri – Chief Executive Officer Madhav Vasanthavada – Chief Commercial Officer and Head-Business Development Brian Kevany – Chief Technical Officer Joe Vazzano – Chief Financial Officer Conference Call Par...
Neutral
GlobeNewsWire
about one month ago
FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025
Neutral
GlobeNewsWire
about 2 months ago
CLEVELAND, March 04, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona's Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., will present at the Leerink Partners Global Healthcare Conference in Miami, Florida on Monday, March 10, 2025 at 3:00 p.m.
Neutral
GlobeNewsWire
about 2 months ago
CLEVELAND, March 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today